Navigation Links
Addex highlights strength of allosteric modulation technology platform
Date:11/12/2010

Geneva, Switzerland, 12 November 2010 Allosteric modulation company Addex Pharmaceuticals (SIX:ADXN) announced today that data on a total of nine therapeutic programs will be presented during Society for Neuroscience 2010 (November 13-17, San Diego, USA), highlighting the strength of its allosteric modulation technology platform. The data being presented cover multiple receptor types and therapeutic areas, including Parkinson's disease, schizophrenia, anxiety, Alzheimer's disease and depression.

"The data generated by Addex and our partners, Ortho-McNeil-Janssen and Merck & Co., being presented at the Society for Neuroscience 2010 conference illustrate the power of our allosteric modulation product generating engine. Although the targets we are addressing have been pursued for many years with standard discovery technologies, most have proven elusive," explained Dr. Vincent Mutel, CEO of Addex. "Our technology is allowing us to bring a new kind of chemistry to industrial drug discovery efforts and thereby improve discovery productivity, a key bottleneck hindering the pharmaceutical industry. Beyond our presentations at Society for Neuroscience this year, we have recently demonstrated our ability to expand our discovery technology beyond GPCRs, like glutamate receptors, to cover other types of cell surface receptors, such as cytokine receptors, including TNF receptors. In addition to advancing our own molecules, we will look to sign multiple collaborative partnerships to realize the potential of our platform."

Small molecule allosteric modulators represent an unexploited kind of chemistry which is different from the traditional small molecule drugs. Orally available allosteric modulators can offer multiple competitive advantages over classical drugs. Most importantly, they can be more specific for their target receptor in the body, while at the same time, offering more precise control over receptor function. They can do this because they bind to cell surface receptors at a different site than traditional drugs. Although allosteric binding sites offer greater control, molecules that bind them cannot be identified using conventional high throughput screening techniques.

Society for Neuroscience 2010 Presentations

Sun, Nov 14, 8:00 - 9:00 AM
162.9/V17 - Novel triazinedione derivatives as GABAB receptor positive allosteric modulators: Synthesis, in vitro pharmacological characterization, pharmacokinetic profile and in vivo activity in rodent model of anxiety

Mon, Nov 15, 8:00 - 9:00 AM
406.9/MMM57 - An mGluR2/3 negative allosteric modulator improves recognition memory assessed by natural forgetting in the novel object recognition test in the rat

Mon, Nov 15, 2:00 - 3:00 PM
514.14/OOO34 - Validating the role of mGluR4 receptors in the physiopathology of anxiety using a selective mGluR4 positive allosteric modulator

Tue, Nov 16, 11:00 AM - 12:00 PM
557.12/M18 - Anti-parkinsonian and anti-dyskinetic effects of ADX48621, a novel mGlu5 negative allosteric modulator

Tue, Nov 16, 1:00 - 2:00 PM
642.5/E29 - JNJ-40068782: A novel potent, selective and systemically active positive allosteric modulator of the mGlu2 receptor

Tue, Nov 16, 2:00 - 3:00 PM
643.22/F23 - Identification and characterization of radioligands that bind to an allosteric modulator site on the mGlur4 receptor

Tue, Nov 16, 3:00 - 4:00 PM
651.15/I6 - Selective mGluR2 negative allosteric modulators reverse the scopolamine-induced deficit in the novel object recognition test

Wed, Nov 17, 2:00 - 3:00 PM
886.14/VV7 - Effects of a mGluR2/3 negative allosteric modulator and a reference mGluR2/3 orthosteric antagonist in a genetic mouse model of depression

Wed, Nov 17, 3:00 - 4:00 PM
885.11/TT19 - Development of a cAMP BRET cellular HTS assay to characterize pharmacological properties of mGluR7 ligands


'/>"/>

Contact: Mike Sinclair
msinclair@halsin.com
44-207-318-2955
Halsin Partners
Source:Eurekalert

Related medicine news :

1. Mayo Clinic Proceedings: November highlights
2. UCI non-small cell lung cancer study highlights advances in targeted drug therapy
3. New study highlights sexual behavior, condom use by US individuals ages 14 to 94
4. 2010 AAO-HNSF new research daily highlights: Wednesday, Sept. 29, 2010
5. Medicinal cannabis review highlights dilemmas facing health care professionals
6. AWARD Fellowship highlights critical role of African women in agricultural research
7. Trainee publication highlights success of US-China agricultural injury research training project
8. Patient safety highlights American Association of Physicists in Medicine
9. Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010
10. STDTestExpress Highlights National HIV Testing Day with Free HIV Testing
11. Survey highlights major Canada-US differences in people in middle age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
Breaking Medicine Technology: